Abstract: To explore the possibility of hepatitis B core antibody (anti-HBc) in predicting hepatitis B virus surface antigen (HBsAg) clearance. Sixty cases with chronic hepatitis B who were previously treated with peginterferon α-2a combined with nucleos(t)ide analogues (NAs) antiviral therapy were divided according to the HBsAg clearance or non-clearance; 41 cases in the clearance group and 19 cases in the non-clearance group. Double antigen sandwich method was used to detect patients anti-HBc quantitative levels during the course of treatment and at baseline, 24, 48, 72 and 96 weeks. Logistic regression analysis and receiver operating characteristic curve (ROC) were used to evaluate the predictive ability of related influencing factors for HBsAg clearance. With antiviral treatment prolongation, anti-HBC quantitative levels in the overall population showed a progressive downward trend in the clearance group and the non-clearance group, but the anti-HBC level in the clearance group was significantly higher than non-clearance group at the baseline and successive detection time points during the antiviral treatment ( < 0.05). Multivariate logistic regression showed that baseline quantitative anti-HBC level, HBsAg decline at week 24 (log10 IU / ml), and alanine aminotransferase (ALT) > 1.5 times the upper limit of normal value (ULN) were all influencing factors for HBsAg clearance during the treatment ( = 0.156, = 0.026; = 0.134, = 0.023; = 0.239, = 0.028). Among them, the baseline quantitative anti-HBc level was the best independent predictor for HBsAg clearance ( = 0.235; = 0.004), and the sensitivity and specificity for predicting HBsAg clearance at > 3.40 log10 IU/ mL were 56.1% and 89.5%, respectively. Logistic regression model was used as a reference to construct combined predictors in order to improve the prediction accuracy. Among them, the combined factor 3 had the highest predictive value (the area under the ROC curve had reached up to 0.870; 95%CI was 0.781 ~ 0.960; < 0.001). The cut-off value of combined factor 3 was > 0.386, and the sensitivity and specificity were 80.5% and 78.9%, respectively. In addition, the combined index had further improved the predictive value, which is the combination of any two or more indexes based on the baseline quantitative anti-HBC level, and HBsAg clearance predictive rate had reached 94.12% ~ 100%. The baseline quantitative anti-HBC level has the highest predictive value for HBsAg clearance. The combination of ALT > 1.5×ULN and HBsAg decline at 24 weeks during the treatment can more precisely predict HBsAg clearance. Therefore, it is a reliable non-invasive biomarker.

[Clinical significance and research progress of quantitative hepatitis B virus core antibody measurement]

Clinical Significance of Quantitative Level of Hepatitis B Core Antibody

Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease

Quantitative Hepatitis B Core Antibody Level May Help Predict Treatment Response in Chronic Hepatitis B Patients

Hepatitis B Core Antibody Level: A Surrogate Marker for Host Antiviral Immunity in Chronic Hepatitis B Virus Infections

Quantitative Hepatitis B Core Antibody Levels in the Natural History of Hepatitis B Virus Infection.

The Measurement of HBV DNA in peripheral blood mononuclear cells and its clinical applicability

Clinical Diagnostic Value of Quantitative Hepatitis B Virus Core Antibody Test in Chronic Viral Hepatitis B

Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.

Quantitative HBV Core Antibodies as a Prognostic Marker for HBeAg Seroclearance: A Systematic Review with Meta-Analysis

Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir

Baseline Quantitative Hepatitis B Core Antibody Titre Alone Strongly Predicts HBeAg Seroconversion Across Chronic Hepatitis B Patients Treated with Peginterferon or Nucleos(t)ide Analogues.

Quantitative hepatitis B core antibody levels can be used as a predictive index of HBsAg clearance

[Research progress of biomarkers of hepatitis B virus and clinical significance]

Role of Quantitative Hepatitis B Core Antibody Levels in Predicting Significant Liver Inflammation in Chronic Hepatitis B Patients with Normal or Near-Normal Alanine Aminotransferase Levels.

Clinical significance and research progress of five serum markers of hepatitis B virus

Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas

Clinical Significance and Remaining Issues of Anti-HBc Antibody and HBV Core-Related Antigen

Clinical application and value of hepatitis B surface antigen quantitation in diagnosis and treatment of chronic hepatitis B

Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase

Distinct Patterns of Serum Hepatitis B Core-Related Antigen During the Natural History of Chronic Hepatitis B